CurrentNeighborhood Health Plan of Rhode IslandPolicy N/A

setmelanotide (Imcivree) — Coverage Criteria for Genetic Obesity

Clinical coverage criteria and authorization rules for Imcivree (setmelanotide) to treat genetic forms of obesity for Medicaid members; includes initial and continuation authorization, quantity limits, and required documentation. Affects providers prescribing or consulting on treatment for eligible patients.

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

Policysetmelanotide (Imcivree) — Coverage Criteria for Genetic Obesity

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionSubmit documentation of genetic testing confirming causative POMC/PCSK1/LEPR variants and evidence of obesity (BMI or percentile) to support a 6-month initial authorization.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

6 moInitial authorization duration

6 moContinuation duration

10 vials/30dQuantity limit

>=6Minimum age

CrCl>30Renal requirement

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for setmelanotide (Imcivree)

inv-01: COVERAGE CRITERIA — Authorization of 6 months may be granted when ALL of the following are met:

Authorization of 6 months may be granted when ALL of the following are met:

Initial authorization general requirements

Age and prescriber: Patient is 6 years or older AND prescribed by or in consultation with an endocrinologist, a geneticist, or a physician who specializes in metabolic disorders
Prior bariatric surgery: Patient has not undergone prior bariatric surgery resulting in >10% weight loss that was maintained
Renal function: Creatinine clearance (CrCl) > 30 mL/min>30 mL/min

Indication-specific criteria

Bardet-Biedl syndrome: Documented diagnosis of Bardet-Biedl syndrome AND documented obesity defined as: adults (≥16 years) BMI ≥ 30 kg/m2 OR ages 6–15 years >97th percentile on growth charts
POMC/PCSK1/LEPR deficiency: Documented obesity (adults BMI >30 kg/m2; pediatric patients >95th percentile on growth charts) AND obesity due to homozygous or compound heterozygous variants in POMC, PCSK1, or LEPR confirmed by genetic testing with variants interpreted as pathogenic, likely pathogenic, or of uncertain significance
Provide genetic testing documentation confirming variant interpretation

inv-02: COVERAGE CRITERIA — Continuation authorization of 6 months for members tolerating treatment with documented positive clinical response

Authorization of 6 months may be granted for members who are tolerating treatment and have documentation of a positive clinical response, as evidenced by:

Response criteria

Adult/General response: At least 5% reduction in baseline body weight≥5%
Pediatric with growth: At least 5% reduction in baseline BMI for patients with continued growth potential≥5% BMI reduction

Patients with impaired renal function do not meet the renal threshold for approval. Specifically, approval requires a creatinine clearance greater than 30 mL/min; patients with a calculated CrCl ≤30 mL/min are excluded.

This therapy is not supported for very young children or for patients with prior effective bariatric surgery. The policy requires a minimum age of 6 years for initial approval; patients who are younger than 6 years are excluded. In addition, patients who have undergone prior bariatric surgery that resulted in more than a 10% weight loss that was maintained are not eligible for coverage.

Product, Quantity and Clinical Thresholds

Quantity limit detailsmixed

Quantity limit

10 vials (10 mg/mL) per 30 days

Age and BMI / Growth Percentiles

Minimum agePatient must be 6 years or older for initial approval

Adult BMI thresholdAdults: BMI ≥ 30 kg/m2 (Bardet‑Biedl) or BMI > 30 kg/m2 (POMC/PCSK1/LEPR) depending on indication

Pediatric growth percentile (Bardet‑Biedl)Ages 6–15 years: >97th percentile on growth charts

Pediatric growth percentile (POMC/PCSK1/LEPR)Pediatric patients: >95th percentile on growth charts

Renal Function Requirement

Required renal functionCreatinine clearance (CrCl) must be greater than 30 mL/min

Prescriber Requirements, Documentation, and Authorization Process

Prior Authorization

Initial 6-month authorization — provider specialty and initial-therapy criteria

Initial authorization may be granted for up to 6 months when all initial-therapy criteria are met. Authorization rules: patient must be ≥ 6 years old, prescribed by or in consultation with an endocrinologist/geneticist/metabolic specialist, no prior sustained >10% weight-loss bariatric surgery, and CrCl > 30 mL/min. Highlight these requirements when submitting prior authorization.

Initial authorization duration: 6 months
Age requirement: ≥ 6 years
Provider requirement: Prescribed by or in consultation with an endocrinologist, geneticist, or metabolic disorder specialist
No prior bariatric surgery with >10% maintained weight loss
Renal function: CrCl > 30 mL/min

Note

No step therapy specified — informational provider action / process note

No step therapy is specified in this policy. Providers do not need to document trials of other agents prior to requesting authorization under these criteria.

Background

Setmelanotide (Imcivree) is indicated for select rare, genetically driven forms of obesity. Coverage is limited to patients meeting documented diagnostic criteria for those genetic syndromes and requires specialist involvement; the policy’s initial authorization criteria specify age, specialist prescriber/consultation, absence of prior bariatric surgery with sustained >10% weight loss, and adequate renal function (CrCl >30 mL/min).

Definitions and Obesity Thresholds

Obesity Definition — Bardet‑Biedl Syndrome

Adult threshold (Bardet‑Biedl)Adults (≥16 years): BMI ≥ 30 kg/m2

Pediatric threshold (Bardet‑Biedl)Ages 6–15 years: >97th percentile on growth charts

Diagnosis requirementDocumented diagnosis of Bardet‑Biedl syndrome is required in addition to obesity criteria

Obesity Definition — POMC / PCSK1 / LEPR Deficiencies

Adult threshold (POMC/PCSK1/LEPR)Adults: BMI > 30 kg/m2

Pediatric threshold (POMC/PCSK1/LEPR)Pediatric patients: >95th percentile on growth charts

Genetic confirmation requirement

Policy Summary

PayerNeighborhood Health Plan of Rhode Island

Policysetmelanotide (Imcivree) — Coverage Criteria for Genetic Obesity

Policy CodePolicy N/A

Change TypeNo material change

Effective DateN/A

Next Review DateN/A

Key ActionSubmit documentation of genetic testing confirming causative POMC/PCSK1/LEPR variants and evidence of obesity (BMI or percentile) to support a 6-month initial authorization.

SourceLink

On This Page

Exclusion for low CrCl

Patients with CrCl ≤ 30 mL/min are excluded from approval

Citation contextRenal function is a required criterion for initial authorization

Documentation Required

Genetic testing documentation — require documentation confirming homozygous or compound heterozygous variants in POMC, PCSK1, or LEPR genes

For POMC, PCSK1, or LEPR genetic indications, genetic testing documentation must be provided and must confirm homozygous or compound heterozygous variants interpreted as pathogenic, likely pathogenic, or of uncertain significance. Include test report and interpretation in the submission.

Required genes: POMC, PCSK1, or LEPR
Required variant status: homozygous or compound heterozygous
Accepted interpretations: pathogenic, likely pathogenic, or uncertain significance
Include full genetic test report and interpretation

Documentation Required

Diagnosis and obesity documentation — require documented diagnosis for syndrome (e.g., Bardet-Biedl) or confirmed gene deficiency and obesity documentation

Diagnosis and obesity documentation must be included: for Bardet-Biedl syndrome, submit documentation of the syndrome diagnosis plus obesity (adults BMI ≥ 30 kg/m2; ages 6–15 > 97th percentile). For POMC/PCSK1/LEPR deficiencies, submit diagnosis of obesity (adults BMI > 30 kg/m2; pediatrics > 95th percentile) and confirm genetic cause.

Bardet-Biedl: documented syndrome diagnosis AND obesity (≥16 years: BMI ≥ 30 kg/m2; 6–15 years: >97th percentile)
POMC/PCSK1/LEPR deficiencies: documented obesity (adults BMI > 30 kg/m2; pediatrics >95th percentile) AND genetic confirmation

Denial Risk

Denial risk — conditions increasing denial risk (age <6, CrCl ≤30 mL/min, missing genetic confirmation, etc.)

Denial risk increases when key criteria are missing or not met. Submissions lacking required age, genetic confirmation, obesity documentation, specialty consultation, or with CrCl ≤ 30 mL/min are at high risk for denial.

High denial risk if patient is under 6 years of age
High denial risk if CrCl ≤ 30 mL/min
High denial risk if genetic confirmation (for POMC/PCSK1/LEPR) is missing or does not show required variant status
High denial risk if documented diagnosis of Bardet-Biedl or obesity metrics are missing
High denial risk if prescriber specialty/consultation documentation is not provided

Obesity must be due to homozygous or compound heterozygous variants in POMC, PCSK1, or LEPR confirmed by genetic testing; documentation of testing with variant interpretation (pathogenic, likely pathogenic, or of uncertain significance) is required